Phoenix, Ariz. -- Alliance Medical Corporation, a leading reprocessor of medical devices, announced today that it has received $7.3 million in new funding, positioning the company for continued growth. The Series E financing was secured from a syndicate composed of Merrill Lynch Investment Managers, which invested $5 million and venture capital firms involved in previous rounds of financing with Alliance, including Affinity Capital, Coral Ventures, Delphi Ventures, Apax Partners and Valley Ventures.
Alliance Medical, which now has agreements with almost all major healthcare group purchasing organization and many of the nation's leading independent deliver networks (IDNs), has raised $35.6 million since July 1999.
"Hospitals seeking new cost-cutting initiatives now realize the impressive savings they can generate by reprocessing with Alliance, and this has resulted in significant revenue growth over the past two years, states Alliance CEO Rick Ferreira. "This new round of funding will increase the savings we can offer our customers by allowing us to expand the array of devices Alliance can reprocess and enhancing our customer service arm. Our financial partners have demonstrated their confidence in our ability to solidify our industry position and in the company's potential for future growth."
The $7.3 million in new funding will support Alliance's strategic growth initiatives, including an increase in the number of devices Alliance can reprocess by developing and submitting additional 510(k)s to the Food and Drug Administration (FDA) and the expansion of the company's sales and service infrastructure.
Alliance Medical Corporation is a leading reprocessor of specific single-use medical devices. The company's FDA-cleared services focus on reducing supply costs of hospitals and surgery centers suffering from shrinking reimbursements and increasing costs. Alliance's unique AIM (Assessment, Implementation and Management) program uses clinical implementation teams to provide facilities with the tools needed to maximize their savings from reprocessing.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.